Key terms
About BCDA
BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BCDA news
Mar 13
7:27am ET
BioCardia, StemCardia enter biotherapeutic delivery partnership
Mar 13
7:12am ET
BioCardia Partners with StemCardia for Heart Therapy Trials
Mar 12
7:30am ET
BioCardia announces CMS approval of coverage of CardiAMP Phase III study
Mar 06
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Mar 04
8:05am ET
BioCardia reports interim results from Phase III CardiAMP cell therapy trial
Feb 14
4:39pm ET
BioCardia files to sell 3.02M shares of common stock for holders
Feb 10
4:15am ET
BioCardia Inc Secures Funding Through Private Placement
Feb 10
4:14am ET
BioCardia Inc Conducts Unregistered Equity Securities Sale
Feb 09
4:08am ET
BioCardia Launches Pivotal CardiAMP HF II Trial
Feb 08
7:11am ET
BioCardia announces activation of CardiAMP heart failure II phase 3 study
Jan 31
7:11am ET
BioCardia announces two abstracts accepted at 2024 THT conference
Jan 03
7:12am ET
BioCardia issues letter to shareholders
Dec 19
7:05am ET
BioCardia doses first patient in CardiALLO Phase I/II trial of BCDA-03
No recent press releases are available for BCDA
BCDA Financials
Key terms
Ad Feedback
BCDA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BCDA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range